CA3256989A1 - COMPOUNDS FOR INHIBITING KIF18A - Google Patents
COMPOUNDS FOR INHIBITING KIF18AInfo
- Publication number
- CA3256989A1 CA3256989A1 CA3256989A CA3256989A CA3256989A1 CA 3256989 A1 CA3256989 A1 CA 3256989A1 CA 3256989 A CA3256989 A CA 3256989A CA 3256989 A CA3256989 A CA 3256989A CA 3256989 A1 CA3256989 A1 CA 3256989A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- optionally substituted
- cycloalkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336183P | 2022-04-28 | 2022-04-28 | |
| US63/336,183 | 2022-04-28 | ||
| US202263389237P | 2022-07-14 | 2022-07-14 | |
| US63/389,237 | 2022-07-14 | ||
| US202363456342P | 2023-03-31 | 2023-03-31 | |
| US63/456,342 | 2023-03-31 | ||
| PCT/US2023/020268 WO2023212240A1 (en) | 2022-04-28 | 2023-04-27 | Compounds for inhibiting kif18a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3256989A1 true CA3256989A1 (en) | 2023-11-02 |
Family
ID=86604316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3256989A Pending CA3256989A1 (en) | 2022-04-28 | 2023-04-27 | COMPOUNDS FOR INHIBITING KIF18A |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230382889A1 (enExample) |
| EP (1) | EP4514790A1 (enExample) |
| JP (1) | JP2025515484A (enExample) |
| KR (1) | KR20250021398A (enExample) |
| CN (1) | CN119451951A (enExample) |
| AU (1) | AU2023261964A1 (enExample) |
| CA (1) | CA3256989A1 (enExample) |
| IL (1) | IL316450A (enExample) |
| MX (1) | MX2024013215A (enExample) |
| TW (1) | TW202346288A (enExample) |
| WO (1) | WO2023212240A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| WO2023028564A1 (en) | 2021-08-26 | 2023-03-02 | Volastra Therapeutics, Inc. | Spiro indoline inhibitors of kif18a |
| AU2023254325A1 (en) * | 2022-04-15 | 2024-10-17 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Kif18a inhibitor and use thereof |
| WO2024039829A1 (en) | 2022-08-18 | 2024-02-22 | Accent Therapeutics, Inc. | Inhibitors of kif18a and uses thereof |
| WO2025020624A1 (zh) * | 2023-07-25 | 2025-01-30 | 捷思英达控股有限公司 | 一种苯环衍生物、其制备方法及其在医药上的应用 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025090640A1 (en) | 2023-10-23 | 2025-05-01 | Volastra Therapeutics, Inc. | Solid formulations and polymorphic forms of indoline inhibitors of kif18a |
| WO2025247067A1 (zh) * | 2024-05-29 | 2025-12-04 | 上海复星医药产业发展有限公司 | Kif18A抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| CA3123227A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| MX2021007157A (es) * | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
| US12540129B2 (en) * | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| CN114302880B (zh) * | 2019-08-02 | 2025-07-15 | 美国安进公司 | Kif18a抑制剂 |
| CA3224249A1 (en) * | 2021-06-25 | 2022-12-29 | Hangzhou Innogate Pharma Co., Ltd. | Compound as kif18a inhibitor |
-
2023
- 2023-04-27 JP JP2024563541A patent/JP2025515484A/ja active Pending
- 2023-04-27 IL IL316450A patent/IL316450A/en unknown
- 2023-04-27 TW TW112115805A patent/TW202346288A/zh unknown
- 2023-04-27 EP EP23726722.4A patent/EP4514790A1/en active Pending
- 2023-04-27 AU AU2023261964A patent/AU2023261964A1/en active Pending
- 2023-04-27 CN CN202380045162.4A patent/CN119451951A/zh active Pending
- 2023-04-27 CA CA3256989A patent/CA3256989A1/en active Pending
- 2023-04-27 WO PCT/US2023/020268 patent/WO2023212240A1/en not_active Ceased
- 2023-04-27 KR KR1020247039543A patent/KR20250021398A/ko active Pending
- 2023-04-27 US US18/140,533 patent/US20230382889A1/en active Pending
-
2024
- 2024-10-25 MX MX2024013215A patent/MX2024013215A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4514790A1 (en) | 2025-03-05 |
| IL316450A (en) | 2024-12-01 |
| WO2023212240A1 (en) | 2023-11-02 |
| MX2024013215A (es) | 2024-12-06 |
| TW202346288A (zh) | 2023-12-01 |
| US20230382889A1 (en) | 2023-11-30 |
| AU2023261964A1 (en) | 2024-11-07 |
| KR20250021398A (ko) | 2025-02-12 |
| CN119451951A (zh) | 2025-02-14 |
| JP2025515484A (ja) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230382889A1 (en) | Compounds for inhibiting kif18a | |
| JP7112324B2 (ja) | Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体 | |
| KR102759231B1 (ko) | 키나제 억제제로서의 아미노피롤로트리아진 | |
| AU2015236428B2 (en) | TrkA kinase inhibitors, compositions and methods thereof | |
| CN104254533B (zh) | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 | |
| CN104169275B (zh) | 用作激酶抑制剂的三唑取代的吡啶化合物 | |
| JP6013375B2 (ja) | キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体 | |
| CN104159896B (zh) | 用作激酶抑制剂的杂环取代的吡啶基化合物 | |
| JP2021520350A (ja) | Ｂｒｍ標的化化合物および関連使用方法 | |
| IL285246B2 (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
| AU2022334480A1 (en) | Spiro indoline inhibitors of kif18a | |
| AU2017359023A1 (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
| US20240174683A1 (en) | Map4k1 inhibitors | |
| TW202440092A (zh) | Akt1之共價修飾劑及其用途 | |
| CA3199333A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| IL297624B1 (en) | Cycloalkyl pyrimidines as ferroportin inhibitors | |
| WO2024010762A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| US20260069602A1 (en) | Compounds, compositions, and methods | |
| CA3022793C (en) | Aromatic sulfonamide derivatives | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241023 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250127 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250127 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250221 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250305 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250305 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250305 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260303 |